Zhiyan Qian

Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

Rita Andraos, Zhiyan Qian, Débora Bonenfant et al. · Cancer Discovery · 2012 · 130 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease

Emeline Evrot, Nicolas Ebel, Vincent Romanet et al. · Clinical Cancer Research · 2013 · 82 citations

Medicine, Pharmacology, Pharmacotherapy +14

Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue

Patrick Chêne, Joëlle Rudloff, Joseph Schoepfer et al. · BMC Chemical Biology · 2009 · 81 citations · Full text

Medicine, Oncology, Pharmacology +15

Improved Efficacy Upon Combined JAK1/2 and Pan-Deacetylase Inhibition Using Ruxolitinib (INC424) and Panobinostat (LBH589) in Preclinical Mouse Models of JAK2V617F-Driven Disease

Fabienne Baffert, Emeline Evrot, Nicolas Ebel et al. · Blood · 2011 · 28 citations

Life Sciences, Pharmacology, Pharmacotherapy +13

Bim and Mcl-1 exert key roles in regulating JAK2V617Fcell survival

Joëlle Rubert, Zhiyan Qian, Rita Andraos et al. · BMC Cancer · 2011 · 25 citations · Full text

Life Sciences, Cell Biology, Hematology +14